SCHEDULE: Cormorant Asset Management Reports Stake in Corbus Pharma

Cormorant Asset Management, LP and Bihua Chen have reported a combined 7.76% beneficial ownership in Corbus Pharmaceuticals Holdings, Inc.

Summary

• Cormorant Asset Management, LP and Bihua Chen have jointly filed a Schedule 13G, indicating a change in beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock.
• The filing reports a combined beneficial ownership of 1,500,000 shares, representing 7.76% of the outstanding common stock.
• This ownership stake is based on the number of shares outstanding as of August 4, 2026, as reported in Corbus Pharmaceuticals' Form 10-Q filed on August 6, 2026.
• Cormorant Asset Management, LP acts as the investment manager for the Cormorant Global Healthcare Master Fund, LP, which holds the shares.
• Bihua Chen, as the managing member of the general partner of Cormorant and the general partner of the Master Fund, is also associated with this beneficial ownership.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without disclosing new strategic information or financial performance.

Positives

• Increased institutional interest indicated by the reporting of a significant ownership stake.
• Transparency provided through the regulatory filing regarding beneficial ownership.

Negatives

• The filing does not provide any new strategic information or financial performance updates for Corbus Pharmaceuticals.
• The nature of Cormorant's investment strategy or intent regarding Corbus Pharmaceuticals is not disclosed.

Risks

• Potential for increased market volatility if Cormorant Asset Management's intentions are perceived as aggressive or opportunistic.
• The filing does not offer insights into Corbus Pharmaceuticals' operational or financial health, leaving investors to rely on other sources for risk assessment.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. The healthcare sector, particularly biopharmaceuticals, often sees significant activity from specialized investment funds like Cormorant Asset Management, which may take positions based on clinical trial results or market potential.

Comparison to Industry Standards

• Passive investment stakes in the pharmaceutical sector typically range from 5% to 15% for institutional investors seeking to influence strategy or awaiting specific catalysts.
• The 7.76% stake reported by Cormorant Asset Management is a substantial minority position, common for investment firms that may engage with management or hold for long-term appreciation.

Stakeholder Impact

• Shareholders may see increased trading volume due to the reporting of a significant stake by an institutional investor.
• Management of Corbus Pharmaceuticals will be aware of Cormorant Asset Management's position and may engage with them regarding company strategy.

Next Steps

• Monitor future filings from Cormorant Asset Management for any changes in ownership or disclosed intentions.
• Observe Corbus Pharmaceuticals' strategic developments and financial performance for insights into the investment's potential.

Key Dates

Keywords

Corbus Pharmaceuticals, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, Investment Management, Healthcare Master Fund, Common Stock